Cationic Lipids for Cell Transfection via Dual-Function Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids are ineffective for transfecting certain cell types, such as cells in suspension and quiescent cells, due to low membrane attachment capacity and require additional targeting elements, leading to complex formulations and limited effectiveness, and they suffer from high toxicity and enzymatic degradation in vivo.
Innovation Solution
Development of a new family of cationic lipids that integrate complexation functions with nucleic acids and targeting capabilities within the same molecule, allowing for non-covalent association with proteins and other biomolecules, providing biodegradability and reduced cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional cationic lipids are used for transfection, then they can deliver nucleic acids to adherent cells, but they are ineffective for suspension cells and quiescent cells due to low membrane attachment capacity
Solution Approach 1:
The patent applies universality by designing cationic lipids with dual functions: membrane attachment capability through polyanionic interactions and nuclear targeting through basic amino acid sequences. This multi-functionality enables the same lipid to effectively transfect diverse cell types including adherent cells, suspension cells, and quiescent cells, resolving the contradiction between adaptability and reliability.
Solution Approach 2:
The patent uses composite materials by combining multiple functional elements into a single cationic lipid molecule: hydrophobic fatty acid chains for membrane integration, cationic head groups for polyanionic interactions, and basic amino acid sequences for nuclear targeting. This composite structure achieves both membrane attachment and nuclear delivery, improving transfection efficiency across different cell types.
2Reliability
If additional targeting elements are added to cationic lipids to improve transfection of hard-to-transfect cells, then transfection efficiency improves, but formulation complexity increases
Solution Approach 1:
The patent merges membrane attachment and nuclear targeting functions into a single integrated cationic lipid molecule. The basic amino acid sequences are incorporated directly into the lipid structure, eliminating the need for separate targeting elements or complex multi-component formulations. This integration maintains high transfection efficiency while reducing formulation complexity.
Solution Approach 2:
By designing the cationic lipid to perform multiple functions simultaneously (membrane attachment, nuclear targeting, and complexation), the patent eliminates the need for additional separate targeting elements. This multi-functionality achieves effective transfection of hard-to-transfect cells without increasing formulation complexity.
3Productivity
If conventional cationic lipids are used for intracellular delivery, then they can transport biologically active agents, but they exhibit high toxicity and enzymatic degradation in vivo
Solution Approach 1:
The patent changes the chemical parameters of the cationic lipid by incorporating biodegradable components such as ester groups and specific amino acid sequences. These parameter changes enable the lipid to be metabolized by cellular enzymes, reducing accumulation and cytotoxicity while maintaining delivery efficiency. The modified lipid structure allows for controlled degradation into non-toxic products.
Solution Approach 2:
The patent employs biodegradable cationic lipids that are designed to be temporarily active and then degraded. The lipid performs its delivery function and is subsequently broken down into non-toxic metabolites, eliminating long-term toxicity concerns. This approach treats the lipid as a temporary carrier that completes its mission and is then discarded metabolically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new cationic lipids enable efficient and non-toxic delivery of nucleic acids, peptides, proteins, and polysaccharides into cells, including hard-to-transfect cell types, with improved stability in serum and reduced toxicity, facilitating effective gene therapy and intracellular delivery of therapeutic molecules.
Implementation Method 1
form complexes (polyplexes, lipoplexes or lipopolyplexes) with nucleic acids via electrostatic interactions
Implementation Method 2
low capacity of lipoplexes to attach to the surface of these cells. Indeed, unlike adherent cells, these possess very few polyanionic transmembrane proteins such as Heparan Sulfate Proteoglycans (HSPGs) which are the main anchoring points of lipoplexes on plasma membranes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The subject of the present invention is the development of a new family of cationic lipids and the use thereof as vectors for in vitro, ex vivo and in vivo delivery of biologically active agents.